TY - JOUR
T1 - Serial coronary CT angiography-verified changes in plaque characteristics as an end point
T2 - Evaluation of effect of statin intervention
AU - Inoue, Kaori
AU - Motoyama, Sadako
AU - Sarai, Masayoshi
AU - Sato, Takahisa
AU - Harigaya, Hiroto
AU - Hara, Tomonori
AU - Sanda, Yoshihiro
AU - Anno, Hirofumi
AU - Kondo, Takeshi
AU - Wong, Nathan D.
AU - Narula, Jagat
AU - Ozaki, Yukio
PY - 2010/7
Y1 - 2010/7
N2 - Objectives: This study sought to assess, by serial computed tomography angiography (CTA), the effect of statin treatment on coronary plaque morphology. Background: In addition to the assessment of luminal stenosis, CTA also allows characterization of plaque morphology. Large, positively remodeled plaques with large necrotic cores have been reported as indicators of plaque instability. Methods: CTA was performed in 32 patients (26 men, ages 64.3 ± 8.5 years). Of these, 24 received fluvastatin after the baseline study; 8 subjects who refused statin treatment were followed as the control subjects. Serial imaging was performed after a median interval of 12 months. All vessels were examined in every subject, and a 10-mm-long segment was identified for comparison before and after intervention. Total plaque volume, low attenuation plaque (LAP) volume, lumen volume, and remodeling index were calculated. Results: In the statin-treated patients, the total plaque volume (92.3 ± 37.7 vs. 76.4 ± 26.5 mm3, p < 0.01) and LAP volume (4.9 ± 7.8 vs. 1.3 ± 2.3 mm3, p = 0.01) were significantly reduced over time; however, there was no change in the lumen volume (63.9 ± 25.3 vs. 65.2 ± 26.2 mm3, p = 0.59). On the other hand, no change was observed in the CTA characteristics in the control subjects, including total plaque volume (94.4 ± 21.2 vs. 98.4 ± 28.6 mm3, p = 0.48), LAP volume (2.1 ± 3.0 vs. 2.3 ± 3.6 mm3, p = 0.91), and lumen volume (80.5 ± 20.7 vs. 75.0 ± 16.3 mm3, p = 0.26). The plaque volume change (-15.9 ± 22.2 vs. 4.0 ± 14.0 mm3, p = 0.01) and LAP volume change (-3.7 ± 7.0 vs. 0.2 ± 1.5 mm3, p < 0.01) were significantly greater in the statin than the control group. The lumen volume (1.3 ± 15.6 vs. -5.5 ± 13.1 mm3, p = 0.24) and remodeling index (-2.4 ± 6.8% vs. -0.3 ± 6.5%, p = 0.53) did not show the significant differences between the 2 groups. The decrease in the plaque volume was due to reduction in the LAP volume (R = 0.83, p < 0.01), and was not related to any changes in the lumen volume (R = 0.21, p = 0.24). Conclusions: This preliminary study suggests that serial CTA evaluation of coronary plaques allows for the assessment of interval change in the plaque morphology. Statin treatment results in decreases in the plaque and necrotic core volume. The features known to be associated with plaque instability.
AB - Objectives: This study sought to assess, by serial computed tomography angiography (CTA), the effect of statin treatment on coronary plaque morphology. Background: In addition to the assessment of luminal stenosis, CTA also allows characterization of plaque morphology. Large, positively remodeled plaques with large necrotic cores have been reported as indicators of plaque instability. Methods: CTA was performed in 32 patients (26 men, ages 64.3 ± 8.5 years). Of these, 24 received fluvastatin after the baseline study; 8 subjects who refused statin treatment were followed as the control subjects. Serial imaging was performed after a median interval of 12 months. All vessels were examined in every subject, and a 10-mm-long segment was identified for comparison before and after intervention. Total plaque volume, low attenuation plaque (LAP) volume, lumen volume, and remodeling index were calculated. Results: In the statin-treated patients, the total plaque volume (92.3 ± 37.7 vs. 76.4 ± 26.5 mm3, p < 0.01) and LAP volume (4.9 ± 7.8 vs. 1.3 ± 2.3 mm3, p = 0.01) were significantly reduced over time; however, there was no change in the lumen volume (63.9 ± 25.3 vs. 65.2 ± 26.2 mm3, p = 0.59). On the other hand, no change was observed in the CTA characteristics in the control subjects, including total plaque volume (94.4 ± 21.2 vs. 98.4 ± 28.6 mm3, p = 0.48), LAP volume (2.1 ± 3.0 vs. 2.3 ± 3.6 mm3, p = 0.91), and lumen volume (80.5 ± 20.7 vs. 75.0 ± 16.3 mm3, p = 0.26). The plaque volume change (-15.9 ± 22.2 vs. 4.0 ± 14.0 mm3, p = 0.01) and LAP volume change (-3.7 ± 7.0 vs. 0.2 ± 1.5 mm3, p < 0.01) were significantly greater in the statin than the control group. The lumen volume (1.3 ± 15.6 vs. -5.5 ± 13.1 mm3, p = 0.24) and remodeling index (-2.4 ± 6.8% vs. -0.3 ± 6.5%, p = 0.53) did not show the significant differences between the 2 groups. The decrease in the plaque volume was due to reduction in the LAP volume (R = 0.83, p < 0.01), and was not related to any changes in the lumen volume (R = 0.21, p = 0.24). Conclusions: This preliminary study suggests that serial CTA evaluation of coronary plaques allows for the assessment of interval change in the plaque morphology. Statin treatment results in decreases in the plaque and necrotic core volume. The features known to be associated with plaque instability.
UR - http://www.scopus.com/inward/record.url?scp=77956639885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956639885&partnerID=8YFLogxK
U2 - 10.1016/j.jcmg.2010.04.011
DO - 10.1016/j.jcmg.2010.04.011
M3 - Article
C2 - 20633846
AN - SCOPUS:77956639885
SN - 1936-878X
VL - 3
SP - 691
EP - 698
JO - JACC: Cardiovascular Imaging
JF - JACC: Cardiovascular Imaging
IS - 7
ER -